Rankings
▼
Calendar
URGN Q1 2022 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena
URGN
UroGen Pharma Ltd.
$927M
Q1 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$14M
+81.2% YoY
Gross Profit
$12M
88.8% margin
Operating Income
-$22M
-161.9% margin
Net Income
-$28M
-209.3% margin
EPS (Diluted)
$-1.25
QoQ Revenue Growth
-16.1%
Cash Flow
Operating Cash Flow
-$24M
Free Cash Flow
-$24M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$166M
Total Liabilities
$183M
Stockholders' Equity
-$17M
Cash & Equivalents
$105M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$14M
$7M
+81.2%
Gross Profit
$12M
$7M
+82.7%
Operating Income
-$22M
-$26M
+15.9%
Net Income
-$28M
-$26M
-9.5%
Revenue Segments
Jelmyto
$14M
100%
← FY 2022
All Quarters
Q2 2022 →